Get access

Efficacy of a Fixed Combination of Indomethacin, Prochlorperazine, and Caffeine Versus Sumatriptan in Acute Treatment of Multiple Migraine Attacks: A Multicenter, Randomized, Crossover Trial

Authors

  • Vincenzo Di Monda MD,

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author
  • Maria Nicolodi MD,

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author
  • Antonina Aloisio MD,

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author
  • Pierluigi Del Bianco MD,

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author
  • Marco Fonzari MD,

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author
  • Irene Grazioli MD,

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author
  • Carla Uslenghi,

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author
  • Leonardo Vecchiet MD,

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author
  • Federigo Sicuteri MD

    1. From the Neurology Division I, Spedali Civili di Brescia (Dr. Di Monda); the Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache (Drs. Nicolodi and Sicuteri) and the Headache Center, Institute of Medical Clinic IV and Medical Pathology (Dr. Del Bianco), University of Florence; the Institute of Neuropsychiatry, University of Palermo (Dr. Aloisio); the Department of Neurology, San Martino Hospital, Genova (Dr. Fonzari); the Medical Department, Solvay Pharma SpA, Grugliasco (TO) (Dr. Grazioli and Ms. Uslenghi); and the Department of Internal Medicine and Aging, Headache Center, University of Chieti (Dr. Vecchiet), Italy.
    Search for more papers by this author

Address all correspondence to Dr. Irene Grazioli, Solvay Pharma SpA, Via della Libertà 30, 10095 Grugliasco (TO), Italy.

Abstract

Objective.—To compare the efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine suppositories with sumatriptan suppositories in the treatment of 2 consecutive migraine attacks of moderate or severe intensity in a multicenter, randomized, crossover study.

Background.—A fixed combination of indomethacin, prochlorperazine, and caffeine is the most commonly used drug for the acute treatment of migraine in Italy. No studies have been published comparing the efficacy of this combination with sumatriptan, the most widely prescribed of the triptans.

Methods.—One hundred twelve patients with migraine with or without aura according to the diagnostic criteria of the International Headache Society were randomized to treat 2 migraine attacks with a fixed combination of indomethacin, prochlorperazine, and caffeine and 2 migraine attacks with sumatriptan. Both drugs were rectally administered in a single dose for each attack. Patients were asked to take study medication as soon as possible at the onset of a headache.

Results.—Of the 112 patients, 88 were compliant to the protocol. More attacks became pain-free at 2 hours postdose (primary end point) on the combination than on sumatriptan (49% versus 34%; P < .01), while there was no difference in the relief of headache at 2 hours postdose (71% versus 65%). The combination was statistically superior to sumatriptan in the time to a pain-free response (a higher percentage of attacks became pain-free from 0.5 hours postdose to 5 hours postdose), in alleviation of nausea, and in a sustained pain-free response (pain-free at 2 hours postdose with no use of rescue medication or relapses within 48 hours). Moreover, a significant consistent response was achieved for the combination compared with sumatriptan across (higher percentage of patients pain-free at 2 hours postdose in the first, second, third, and fourth treated attack) and within patients (pain-free in 2 of 2 treated attacks in 35% of patients taking the combination and 20% of patients on sumatriptan). Both drugs were well-tolerated.

Conclusions.—This study, analyzed according to the more recent guidelines for controlled trials in migraine, showed that a fixed combination of indomethacin, prochlorperazine, and caffeine is significantly more effective than sumatriptan in the acute treatment of migraine attacks. It is notable that the combination is less expensive than sumatriptan per unit dose.

Get access to the full text of this article

Ancillary